FR2397839A1 - Compose donnant un vaccin oral intestinal - Google Patents

Compose donnant un vaccin oral intestinal

Info

Publication number
FR2397839A1
FR2397839A1 FR7721946A FR7721946A FR2397839A1 FR 2397839 A1 FR2397839 A1 FR 2397839A1 FR 7721946 A FR7721946 A FR 7721946A FR 7721946 A FR7721946 A FR 7721946A FR 2397839 A1 FR2397839 A1 FR 2397839A1
Authority
FR
France
Prior art keywords
killed
treating
attenuated
comprises specified
gastroenteritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7721946A
Other languages
English (en)
Other versions
FR2397839B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR7721946A priority Critical patent/FR2397839A1/fr
Publication of FR2397839A1 publication Critical patent/FR2397839A1/fr
Application granted granted Critical
Publication of FR2397839B1 publication Critical patent/FR2397839B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Vaccin oral intestinal. Il contient, en plus des différents germes tués ou atténués suivants : Escherichia coli 0111 B4, E. coli 055 B5, E. coli 026 B6, E. coli 086 B7, E. coli 0127 B8, E. coli 0128 B12, E. coli 0129 B14, E. coli 0125 B15, E. coli 0126 B16, E. coli 0124 B17, E. coli 018, aerobacter aerogenes, aerobacter cloacae, klebisiella pneumoniae, proteus OX 19, pseudomonas aeruginosa, streptococcus faecalis et staphylococcus aureus; des produits destinés à améliorer la flore intestinale, à jouer un rôle dans la synthèse des anticorps locaux. Le médicament destiné à prévenir et à traiter les entéro-gastrites contient des germes tués et/ou atténués, de la méthionine, du gluconate de fer et peut contenir aussi des germes non pathogènes vivants et des vitamines.
FR7721946A 1977-07-18 1977-07-18 Compose donnant un vaccin oral intestinal Granted FR2397839A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7721946A FR2397839A1 (fr) 1977-07-18 1977-07-18 Compose donnant un vaccin oral intestinal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7721946A FR2397839A1 (fr) 1977-07-18 1977-07-18 Compose donnant un vaccin oral intestinal

Publications (2)

Publication Number Publication Date
FR2397839A1 true FR2397839A1 (fr) 1979-02-16
FR2397839B1 FR2397839B1 (fr) 1981-07-03

Family

ID=9193447

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7721946A Granted FR2397839A1 (fr) 1977-07-18 1977-07-18 Compose donnant un vaccin oral intestinal

Country Status (1)

Country Link
FR (1) FR2397839A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606919A (en) * 1984-08-31 1986-08-19 Solco Basel Ag Vaccine for the treatment of urinary tract infections containing aluminum phosphate
WO1996007426A1 (fr) * 1994-09-06 1996-03-14 Auspharm International Limited Vaccin contre des infections vaginales s'administrant par voie enterique
US5538727A (en) * 1982-06-03 1996-07-23 Dcv Biologics, L.P. Anti-cholesterolemic vaccine
US5853765A (en) * 1982-06-03 1998-12-29 Dcv, Inc. Anti-cholesterolemic egg, vaccine and method for production, and use
US6180100B1 (en) * 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
EP1303300A1 (fr) * 2000-06-19 2003-04-23 Candivax Pty Ltd. Compositions et procedes de traitement de la candidiase

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538727A (en) * 1982-06-03 1996-07-23 Dcv Biologics, L.P. Anti-cholesterolemic vaccine
US5853765A (en) * 1982-06-03 1998-12-29 Dcv, Inc. Anti-cholesterolemic egg, vaccine and method for production, and use
US5932250A (en) * 1982-06-03 1999-08-03 Dcv, Inc. Anti-cholesterolemic egg, vaccine and method for production, and use
US4606919A (en) * 1984-08-31 1986-08-19 Solco Basel Ag Vaccine for the treatment of urinary tract infections containing aluminum phosphate
WO1996007426A1 (fr) * 1994-09-06 1996-03-14 Auspharm International Limited Vaccin contre des infections vaginales s'administrant par voie enterique
US6180100B1 (en) * 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
EP1303300A1 (fr) * 2000-06-19 2003-04-23 Candivax Pty Ltd. Compositions et procedes de traitement de la candidiase
EP1303300A4 (fr) * 2000-06-19 2004-03-24 Candivax Pty Ltd Compositions et procedes de traitement de la candidiase

Also Published As

Publication number Publication date
FR2397839B1 (fr) 1981-07-03

Similar Documents

Publication Publication Date Title
WO2001045679A3 (fr) Utilisation d'agents chimiotherapeutiques
CA2414576A1 (fr) Renforcement de la sante globale du corps
AU2295895A (en) Dosage forms and method for ameliorating male erectile dysfunction
EP0077734A3 (fr) Production d'anticorps monoclonaux contre des adhésines bactériennes
AU2118488A (en) Improvements in or relating to methods of treating damaged skin
AU2001271545A1 (en) Promoting whole body health
HU910177D0 (en) Process for the production of medical preparations for peroral entering of phimobendane
MY109143A (en) Sulfonamido-and sulfonamidocarbonylpyridine 2-carboxamides and their pyridine-n-oxides, process for their preparation and their use as pharmaceuticals
BG103474A (en) Application of derivatives of 7-(2-oxa-5,8-diazobicyclo[4,3,0]non-8-8-yl)-quinoloncarboxylic acid and naphthyridoncarboxylic acid in the therapy of helicobacter pylor infections and the gastroduodenal diseases related to them
PT97785A (pt) Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina
FR2397839A1 (fr) Compose donnant un vaccin oral intestinal
RU99107569A (ru) Фармацевтические композиции, обладающие антимикробной активностью
SE9201930D0 (sv) Gastric antibacterial treatment
DE3583562D1 (de) Vakzine zur behandlung der harnwegsinfektionen.
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
ATE178792T1 (de) Orale verwendung von calciumformiat zur behandlung von calciumdefizienz bei tieren
MX170929B (es) Empleo de substancias antigenicas para la profilaxis o la terapia de transtornos y enfermedades en el conducto digestivo de animales y humanos
ES2136206T3 (es) Composicion antibacteriana que contiene alfalactalbumina multimerica.
EP1038524A4 (fr) L-threonate ferreux, composition pharmaceutique le contenant et son utilisation pour reduire et traiter l'anemie chez l'homme
EP0057323A3 (fr) Composition anticariogène
ATE137967T1 (de) Verwendung von ketorolac zur behandlung von periodontitis
IE32044B1 (en) Process for the manufacture of a tetanus-vaccine
CA2103707A1 (fr) Traitement des carcinomes pulmonaires autres que le cancer pulmonaire a petites cellules
WO1990013660A3 (fr) Anticorps monoclonaux humains de determinants sero-specifiques de bacteries gram-negatives
JPS5577890A (en) Preparation of alcohol-resistant high-purity phycocyanin

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property
ST Notification of lapse
ST Notification of lapse
ST Notification of lapse